Evoke Pharma Inc (NASDAQ:EVOK) has received a consensus recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $9.00.
A number of equities research analysts have recently issued reports on EVOK shares. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Evoke Pharma in a report on Tuesday, October 24th. Zacks Investment Research upgraded Evoke Pharma from a “sell” rating to a “hold” rating in a report on Monday, November 20th. B. Riley restated a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a report on Wednesday, November 15th. Northland Securities restated a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a report on Wednesday, October 18th. Finally, FBR & Co restated a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a report on Thursday, October 19th.
Several large investors have recently modified their holdings of the company. Creative Planning acquired a new stake in shares of Evoke Pharma in the fourth quarter valued at approximately $226,000. Sphera Funds Management LTD. raised its position in shares of Evoke Pharma by 14.2% in the third quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after buying an additional 71,022 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after buying an additional 68,544 shares in the last quarter. Institutional investors own 13.64% of the company’s stock.
Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). During the same period last year, the company posted ($0.29) earnings per share. research analysts expect that Evoke Pharma will post -1 EPS for the current year.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.